- Home
- CMBM vs NRXS Comparison
CMBM vs NRXS Comparison
Compare CMBM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- NRXS
- Stock Information
- Founded
- CMBM 2011
- NRXS 2011
- Country
- CMBM United States
- NRXS United States
- Employees
- CMBM N/A
- NRXS N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- NRXS
- Sector
- CMBM Technology
- NRXS
- Exchange
- CMBM Nasdaq
- NRXS Nasdaq
- Market Cap
- CMBM 12.1M
- NRXS 13.0M
- IPO Year
- CMBM 2019
- NRXS 2023
- Fundamental
- Price
- CMBM $0.49
- NRXS $2.22
- Analyst Decision
- CMBM Strong Buy
- NRXS
- Analyst Count
- CMBM 2
- NRXS 0
- Target Price
- CMBM $5.50
- NRXS N/A
- AVG Volume (30 Days)
- CMBM 107.7K
- NRXS 29.8K
- Earning Date
- CMBM 05-23-2025
- NRXS 05-12-2025
- Dividend Yield
- CMBM N/A
- NRXS N/A
- EPS Growth
- CMBM N/A
- NRXS N/A
- EPS
- CMBM N/A
- NRXS N/A
- Revenue
- CMBM $172,215,000.00
- NRXS $2,934,945.00
- Revenue This Year
- CMBM N/A
- NRXS $138,883.78
- Revenue Next Year
- CMBM $17.64
- NRXS $118.59
- P/E Ratio
- CMBM N/A
- NRXS N/A
- Revenue Growth
- CMBM N/A
- NRXS 27.52
- 52 Week Low
- CMBM $0.23
- NRXS $1.33
- 52 Week High
- CMBM $4.16
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- CMBM 56.81
- NRXS 49.81
- Support Level
- CMBM $0.42
- NRXS $1.94
- Resistance Level
- CMBM $0.47
- NRXS $2.42
- Average True Range (ATR)
- CMBM 0.04
- NRXS 0.26
- MACD
- CMBM 0.02
- NRXS 0.00
- Stochastic Oscillator
- CMBM 78.90
- NRXS 40.99
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).